Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The company performed particularly well in operational eco-efficiency, environmental and social reporting
Company working on COVID vaccine INO 4800
Company to launch product after the expiry of semaglutide patent in India
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Subscribe To Our Newsletter & Stay Updated